Velagliflozin (proline)

Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1].

Product Specifications

CAS Number

[1539295-26-5]

UNSPSC

12352005

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/velagliflozin-proline.html

Purity

99.43

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC([C@@H]1CCCN1)=O.O[C@H]2[C@H](C3=CC(CC4=CC=C(C5CC5)C=C4)=C(C#N)C=C3)O[C@H](CO)[C@@H](O)[C@@H]2O

Molecular Formula

C28H34N2O7

Molecular Weight

510.58

References & Citations

[1]Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41 (2) :266-273.|[2]Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13 (9) :e0203655.